Fosun Pharma Unit Wins Clinical Trial Approval for SRT-003-1 Diagnostic Drug

Stock News
Yesterday

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlling subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials of [18F]F-SR031 injection, also known as SRT-003-1, for positron emission tomography (PET) imaging of fibroblast activation protein (FAP)-positive lesions in patients with solid tumors.

The subsidiary plans to initiate a Phase I clinical study of the drug in China once conditions permit.

SRT-003-1 is a radioactive in vivo diagnostic agent targeting fibroblast activation protein (FAP), intended primarily for PET imaging of FAP-positive lesions in solid tumor patients. FAP is a type II transmembrane serine protease belonging to the prolyl oligopeptidase family. It is barely expressed in normal tissues but is selectively overexpressed in cancer-associated fibroblasts (CAFs) of various epithelial tumors, including gastric cancer, esophageal cancer, lung cancer, colorectal cancer, and ovarian cancer. FAP inhibitors labeled with fluorine-18F can specifically bind to FAP on the surface of CAFs, causing FAP-overexpressing tumor lesions to show high uptake on PET imaging, thereby enabling tumor diagnosis, staging, and efficacy evaluation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10